ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMLN Stock Price » AMLN Stock News

Amylin Pharmaceuticals Share News

 Amylin Pharmaceuticals (mm) Stock Price
AMLN Stock Price
 Amylin Pharmaceuticals (mm) Stock Chart
AMLN Stock Chart
 Amylin Pharmaceuticals (mm) Stock News
AMLN Stock News
 Amylin Pharmaceuticals (mm) Company Information
AMLN Company Information
 Amylin Pharmaceuticals (mm) Stock Trades
AMLN Stock Trades

Sanofi: New Diabetes Drug Shown To Work As Well As Byetta

French drugs maker Sanofi SA(SNY) said trial data showed its experimental once-a-day drug for Type 2 diabetes, lixisenatide, worked as well as Byetta, a similar drug sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly and Co (LLY) that is injected twice daily. The trial lasted 24 weeks and involved 634 people whose diabetes was not controlled by orally-taken medicines or by using basal insulin. In it, lixisenatide, whose brand name is Lyxumia, met the main goal of showing non-inferiority compared with Byetta, also known as exenatide, in terms of controlling blood sugar, with less risk of low blood sugar, Sanofi said in a statement. The French company also said that mean body weight significantly decreased from baseline in the lixisenatide group compared with the exenatide group, while adverse side effects were generally equal between the two groups. Another study comparing lixisenatide against placebo showed that a once-daily dose of lixisenatide in combination with basal insulin improved blood sugar control in Asian Type 2 diabetes patients. Results of the trials were presented at the current American Diabetes Association's 71st Scientific Sessions (ADA) in San Diego, California. Lixisenatide and exenatide belong to the GLP-1 class of drugs that stimulate insulin release when glucose levels become too high. Sanofi licensed lixisenatide from Denmark's Zealand Pharma (ZEAL.KO). The treatment could become a blockbuster, helping Sanofi reach its goal of becoming the world's top diabetes treatment company. -By Sten Stovall, Dow Jones Newswires; +44 207 842 9292;

Stock News for Amylin Pharmaceuticals (AMLN)
08/09/201208:24:09AstraZeneca: Bristol-Myers Squibb Completes Purchase of Amylin
08/02/201212:30:06Bristol-Myers Executive Charged With Insider Trading
08/02/201212:17:26U.S. Charges Bristol-Myers Executive With Insider Trading
08/02/201211:07:11Bristol-Myers Pension Executive Robert Ramnarine Arrested for...
07/26/201210:24:24Evercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking...
07/25/201208:20:16Bristol-Myers Profit Falls 28%
07/25/201208:00:01Bristol-Myers 2nd-Quarter Profit Falls 28% on Drug-Patent Expirations
07/02/201211:53:36Bristol Sees Commercial Muscle Accelerating Sales of Bydureon
06/29/201223:36:26Bristol-Myers to Buy Amylin Pharmaceuticals for $5.3 Billion
06/10/201220:35:15Novo Nordisk's Victoza More Efficient Than Peers In New Study
06/09/201208:30:11Sanofi's Lantus Cuts Blood Sugar More Than Merck's Januvia in...
06/05/201209:10:47Amylin is Said To Draw First-Round Bids of Up to $29/Share -Bloomberg
04/25/201214:53:05Icahn: Suit Against Amylin Dropped After Talks With CEO
04/19/201213:53:31FDA Is Asked To Remove Novo Nordisk Diabetes Drug From Market
04/09/201213:08:09Icahn Files Lawsuit Against Amylin To Force Nomination Extension
03/28/201210:08:30Amylin Has Rejected $3.5 Billion Buyout Bid By Bristol-Myers...
03/23/201209:08:11Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays

Amylin Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations